15 Stocks Moving in Monday's Pre-Market Session

Gainers

• IceCure Medical Ltd ICCM rose 36.5% to $3.89 in pre-market trading. IceCure Medical, last week, received notice of intention to grant a European patent covering its cryogenic pump.
• American Virtual Cloud Technologies, Inc. AVCT rose 25.8% to $2.39 in pre-market trading after dipping 24% on Thursday.
• RISE Education Cayman Ltd REDU rose 15.3% to $0.6106 in pre-market trading following a 5% surge on Thursday.
• Genocea Biosciences, Inc. GNCA shares rose 12.5% to $1.40 in pre-market trading after gaining around 20% on Thursday.
• Aridis Pharmaceuticals, Inc. ARDS rose 9.8% to $2.90 in pre-market trading. Aridis Pharmaceuticals, last week, announced its fully human monoclonal antibody cocktail AR-701 is broadly reactive against the Omicron and other COVID-19 variants, SARS, MERS and the common cold coronaviruses.
• Orbsat Corp. OSAT rose 8.4% to $4.01 in pre-market trading after dropping over 5% on Thursday. The company, last month, reported Q3 sales of $2.25 million.
• Nxt-ID, Inc. NXTD rose 7% to $4.29 in pre-market trading after surging around 20% on Thursday.
• Inspira Technologies Oxy B.H.N. Ltd. IINN rose 6% to $3.88 in pre-market trading after tumbling 12% on Thursday.
• XpresSpa Group, Inc. XSPA rose 5.5% to $2.11 in pre-market trading.
• Gevo, Inc. GEVO shares rose 5.4% to $5.10 in pre-market trading.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Check out these big penny stock gainers and losers

Losers

• BiondVax Pharmaceuticals Ltd. BVXV fell 15.1% to $2.36 in pre-market trading after the company reported a proposed underwritten public offering of American Depositary Shares.
• Snow Lake Resources Ltd. LITM shares fell 5.9% to $5.46 in pre-market trading after dropping over 3% on Thursday.
• Genfit SA GNFT fell 5.9% to $5.08 in pre-market trading. Genfit and Ipsen recently announced an exclusive licensing agreement for elafibranor.
• Sonnet BioTherapeutics Holdings, Inc. SONN shares fell 5.2% to $0.43 in pre-market trading. Chardan Capital, last week, maintained Sonnet BioTherapeutics with a Buy and lowered the price target from $8 to $2.5.
• Ensysce Biosciences, Inc. ENSC shares fell 4.3% to $4.90 in pre-market trading. Ensysce Biosciences recently said that the first patients have been enrolled in Phase 1 study of PF614-MPAR, its unique technology platform to provide opioid overdose protection.